Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.
Cecilia RossoEugenio De CorsoValerio ContiLetizia NitroAlberto Maria SaibeneElena ParazziniRocco Francesco RinaldoSabrina De PascalisFlavio ArnoneStefano CentanniClaudio MontuoriLeandro Maria D'AuriaGiovanni FelisatiCarlotta PipoloPublished in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2024)
The response to a biologic treatment for CRSwNP control may be heterogenous and it seems that patients may benefit from switching improving control in equal measure in the upper and lower airway. Further studies to explore the endotype/phenotype which best fits with each biologic are mandatory to personalize the therapy.